高性能核心实验室GFAP/UCH-L1检测预测轻度创伤性颅脑损伤后颅内损伤
该研究为ALERT-TBI研究的二次分析,纳入1899例≥18岁、非穿透性颅脑损伤、GCS 9-15且临床需要行头部CT的患者(其中GCS 13-15且有足够库存血样者纳入分析)。以头部CT诊断的创伤性颅内损伤为参照,评估核心实验室快速高通量平台检测GFAP/UCH-L1 panel的检验特征。结果显示panel敏感性96.7%(95%CI 91.7-98.7),特异性40.1%(95%CI 37.8-42.4),阴性预测值99.4%(95%CI 98.6-99.8),阴性似然比0.08(95%CI 0.03-0.22);120例CT阳性患者中panel假阴性4例。作者认为该平台速度快、可同时分析多个样本,在大规模伤亡或急诊量超负荷等CT需求高的情况下可能有额外价值。
要点
- 在GCS 13-15的轻度TBI患者中,核心实验室GFAP/UCH-L1 panel的敏感性为96.7%(95%CI 91.7-98.7),阴性预测值99.4%(95%CI 98.6-99.8)。
- 120例头部CT阳性患者中panel假阴性4例;阴性似然比0.08(95%CI 0.03-0.22)。
- 特异性为40.1%(95%CI 37.8-42.4),提示panel阳性不能单独确认颅内损伤。
- 作者认为核心实验室平台速度快且可同时分析多个样本,在大规模伤亡或急诊量超负荷等CT需求高的情况下可能有额外价值。
适用人群与场景
- 纳入标准:≥18岁、非穿透性颅脑损伤、就诊时GCS 9-15且临床需要行头部CT;本分析纳入其中GCS 13-15且有足够库存血样者。
- 研究数据来自ALERT-TBI研究的临床数据与库存血样。
研究设计与关键结果
- 研究类型:ALERT-TBI研究的二次分析,样本量1899例;平均年龄49.1岁(18至98岁),男性56.5%,白人70.6%。
- 最常见受伤机制为跌倒(51.9%),94.1%就诊时GCS为15。
- 头部CT诊断为创伤性颅内损伤者120例(6.3%),其中panel假阴性4例。
- panel敏感性96.7%(95%CI 91.7-98.7),特异性40.1%(95%CI 37.8-42.4),阴性预测值99.4%(95%CI 98.6-99.8),阴性似然比0.08(95%CI 0.03-0.22)。
证据类型、等级与局限
- 证据类型:ALERT-TBI研究的二次分析(研究论文)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为该核心实验室快速高通量平台检测GFAP/UCH-L1 panel具有高敏感性和阴性预测值,在大规模伤亡或急诊量超负荷等CT需求高的情况下可能有额外价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) blood biomarker panel can reliably eliminate the need to perform a head computed tomography (CT) scan in selected patients with traumatic brain injury (TBI). Currently, this FDA cleared panel can be run both on a core laboratory platform or a hand-held single-sample point of care platform. This study examined test characteristics of the panel as analyzed on a core lab-based fast high-throughput platform.
METHODS: This secondary analysis of clinical data and banked blood samples obtained for the ALERT-TBI study included patients ≥18 years old with nonpenetrating head injury, a presenting Glasgow Coma Scale score 9-15, and a head CT was indicated. Included were patients with a GCS 13-15 who had sufficient banked blood for analysis. Test characteristics of the biomarker panel were determined relative to head CT findings for traumatic intracranial injury.
RESULTS: Among the 1899 included subjects, mean age was 49.1 yrs. (18 to 98 yrs), 56.5 % male, and 70.6 % were Caucasian. The most common mechanism of injury was a fall (51.9 %) and 94.1 % presented with a GCS of 15. Head CT was positive for traumatic intracranial injury in 120 patients (6.3 %) of which the biomarker panel was a false negative in four patients. Sensitivity (95 % confidence interval) of the biomarker panel was 96.7 (91.7, 98.7), specificity 40.1 (37.8, 42.4), negative predictive value 99.4 (98.6, 99.8), and the negative likelihood ratio was 0.08 (0.03, 0.22).
CONCLUSIONS: The biomarker panel, measured on this core lab-based fast high-throughput platform, had high sensitivity and negative predictive values. The core laboratory platform has the advantage of speed and the ability to analyze multiple samples simultaneously suggesting additional utility when there is high need for CT imaging such as mass casualty or emergency department volume overload situations.
参考来源
- Welch RD, Bazarian JJ, Chen JY, et al. A high-performance core laboratory GFAP/UCH-L1 test for the prediction of intracranial injury after mild traumatic brain injury. Am J Emerg Med. 2024. PMID: 39708460. doi:10.1016/j.ajem.2024.12.005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。